Skip to main content
NCBI home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2005 Mar 7;18(1):3–13. doi: 10.1016/S0009-9120(85)80016-3

Abnormalities of serum and plasma components in patients with multiple sclerosis

Henry C Ford 1,*
PMCID: PMC7130298  PMID: 3886192

Abstract

Qualitative and quantitative abnormalities in protein and non-protein components of serum and plasma in patients with multiple sclerosis have been the subjects of numerous reports. In this review many of the more recent observations are documented and evaluated. It is concluded that at present the welter of information that has been gathered does not contribute in any major, coherent way to our understanding of the etiology or pathogenesis of the disorder. Several of the abnormalities that have been observed may be future candidates for biochemical markers for multiple sclerosis; at present none is sufficiently reliable, distinctive or easily performed to warrant the status of a useful diagnostic or prognostic test.

Key Words: multiple sclerosis, plasma, blood, immunoglobulins, serum proteins

References

  • 1.Iivanainen MV. The significance of abnormal immune responses in patients with multiple sclerosis. J Neuroimmunol. 1981;1:141–172. doi: 10.1016/0165-5728(81)90040-0. [DOI] [PubMed] [Google Scholar]
  • 2.Rathke E, Jones M. Serum cerebrosides in multiple sclerosis. J Neurochem. 1974;22:311–313. doi: 10.1111/j.1471-4159.1974.tb11596.x. [DOI] [PubMed] [Google Scholar]
  • 3.Samuelson K. Separation and identification of cerebrosides in cerebrospinal fluid by gas chromatography—mass spectrometry. Scand J Clin Lab Invest. 1971;27:381–391. doi: 10.3109/00365517109080234. [DOI] [PubMed] [Google Scholar]
  • 4.Tourtellotte WW, Haerer AF. Lipids in cerebrospinal fluid. XII. In multiple sclerosis and retrobulbar neuritis. Arch Neurol. 1969;20:605–615. doi: 10.1001/archneur.1969.00480120051004. [DOI] [PubMed] [Google Scholar]
  • 5.Vincent B, Jones M. Plasma cerebrosides in stroke and multiple sclerosis. Ann Clin Lab Sci. 1975;5:45–51. [PubMed] [Google Scholar]
  • 6.Baumann N, Lemonnier M, Jacque C, Marteau R, Harpin ML, Lhermitte F. Plasma galactocerebrosides in multiple sclerosis. Biomedicine. 1975;23:387–390. [PubMed] [Google Scholar]
  • 7.Suzuki K, Kamoshita S, Eto Y, Tourtellotte WW, Gonatas JO. Myelin in multiple sclerosis. Arch Neurol. 1973;28:293–297. doi: 10.1001/archneur.1973.00490230029002. [DOI] [PubMed] [Google Scholar]
  • 8.Nagai Y, Kanfer JN, Tourtellotte WW. Preliminary observations of gangliosides of normal and multiple sclerosis cerebrospinal fluid. Neurology. 1973;23:945–948. doi: 10.1212/wnl.23.9.945. [DOI] [PubMed] [Google Scholar]
  • 9.Ledeen RW, Yu RK. Gangliosides of CSF and plasma: their relation to the nervous system. Adv Exp Med Biol. 1972;19:77–93. [Google Scholar]
  • 10.Sela B-A, Konat G, Offner H. Elevated ganglioside concentration in serum and peripheral blood lymphocytes from multiple sclerosis patients in remission. J Neurol Sci. 1982;54:143–148. doi: 10.1016/0022-510x(82)90226-x. [DOI] [PubMed] [Google Scholar]
  • 11.Miller HC, Esselman WJ. Modulation of the immune response by antigen-reactive lymphocytes after cultivation with gangliosides. J Immunol. 1975;115:839–843. [PubMed] [Google Scholar]
  • 12.Correa M, Miller HC, Esselman WJ. Antigen-induced modulation by shed lymphocyte membrane gangliosides. Immunol Commun. 1980;9:543–557. doi: 10.3109/08820138009052994. [DOI] [PubMed] [Google Scholar]
  • 12.a. Waksman BH, Reynolds WE. Vol. 175. 1984. Multiple sclerosis as a disease of immune regulation; pp. 282–294. (Proc Soc Exp Biol Med). [DOI] [PubMed] [Google Scholar]
  • 13.Huszak I, Rimanoczy A, Latzkovits L, Lehotai L. Phospholipid composition of blood in multiple sclerosis. Acta Med Acad Sci Hung. 1972;29:197–201. [PubMed] [Google Scholar]
  • 14.Karlsson I, Alling C, Svennerholm L. Major plasma lipids and their fatty acid composition in multiple sclerosis and other neurological diseases. Acta Neurol Scand. 1971;47:403–412. doi: 10.1111/j.1600-0404.1971.tb07495.x. [DOI] [PubMed] [Google Scholar]
  • 15.Delmotte P, Ketelaer CJ. Biochemical findings in multiple sclerosis. I. A detailed study of the plasma lipid fractions of 484 multiple sclerosis patients compared with 152 other neurological diseases. J Neurol. 1974;207:27–43. doi: 10.1007/BF00312590. [DOI] [PubMed] [Google Scholar]
  • 16.Andreoli VM, Maffei F, Tonon GC, Zibetti A. Significance of plasma lysolecithin in patients with multiple sclerosis: a longitudinal study. J Neurol Neurosurg Psychiatry. 1973;36:661–667. doi: 10.1136/jnnp.36.4.661. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Baker RWR, Thomson RHS, Zilkha KJ. Serum fatty acids in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1964;27:408–414. doi: 10.1136/jnnp.27.5.408. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Tichy J, Vymazal J. Changes of some serum fatty acids and lipids in relation to the clinical course of multiple sclerosis. Acta Neurol Scand. 1973;49:345–354. doi: 10.1111/j.1600-0404.1973.tb01308.x. [DOI] [PubMed] [Google Scholar]
  • 19.Love WC, Cashell A, Reynolds M, Callaghan N. Linoleate and fatty-acid patterns of serum lipids in multiple sclerosis and other diseases. Br Med J. 1974;3:18–21. doi: 10.1136/bmj.3.5922.18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Wolfgram F, Myers L, Ellison G, Knipprath W. Serum linoleic acid in multiple sclerosis. Neurology. 1975;25:786–788. doi: 10.1212/wnl.25.8.786. [DOI] [PubMed] [Google Scholar]
  • 21.Heipertz R, Klauke W, Pilz H, Ritter G. Serum fatty acids in multiple sclerosis. J Neurol. 1977;214:153–157. doi: 10.1007/BF02430352. [DOI] [PubMed] [Google Scholar]
  • 22.Shukla VKS, Clausen J. Linoleate and fatty acid patterns of serum lipids in multiple sclerosis. Acta Neurol Scand. 1978;57:270–274. doi: 10.1111/j.1600-0404.1978.tb05875.x. [DOI] [PubMed] [Google Scholar]
  • 23.Neu IS. Essential fatty acids in the serum and cerebrospinal fluid of multiple sclerosis patients. Acta Neurol Scand. 1983;67:151–163. doi: 10.1111/j.1600-0404.1983.tb04558.x. [DOI] [PubMed] [Google Scholar]
  • 24.Field EJ, Joyce G. Simplified laboratory test for multiple sclerosis. Lancet. 1976;2:367–368. doi: 10.1016/s0140-6736(76)92623-4. [DOI] [PubMed] [Google Scholar]
  • 25.Millar JHD, Zilkha KJ, Langman MJS, Payling Wright H, Smith AD, Belin J, Thompson RHS. Double-blind trial of linoleate supplementation of the diet in multiple sclerosis. Br Med J. 1973;1:765–768. doi: 10.1136/bmj.1.5856.765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Bates D, Fawcett PRW, Shaw DA, Weightman D. Polyunsaturated fatty acids in treatment of acute remitting multiple sclerosis. Br Med J. 1978;2:1390–1391. doi: 10.1136/bmj.2.6149.1390. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Palm R, Hallmans G. Zinc and copper in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1982;45:691–698. doi: 10.1136/jnnp.45.8.691. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Wong EK, Jr, Enomoto H, Leopold IH. Plasma zinc levels in multiple sclerosis. Metab Pediatr Syst Ophthalmol. 1980;4:3–8. [PubMed] [Google Scholar]
  • 29.Dore-Duffy P, Catalanotto F, Donaldson JO, Ostrom KM, Testa MA. Zinc in multiple sclerosis. Ann Neurol. 1983;14:450–454. doi: 10.1002/ana.410140409. [DOI] [PubMed] [Google Scholar]
  • 30.Rieder HP, Schoettli G, Seiler H. Trace elements in whole blood of multiple sclerosis. Eur Neurol. 1983;22:85–92. doi: 10.1159/000115542. [DOI] [PubMed] [Google Scholar]
  • 31.Iijima K, Takase S, Tsumuraya K, Endo M, Itahara K. Changes in free amino acids of cerebrospinal fluid and plasma in various neurological diseases. Tohoku J Exp Med. 1978;126:133–150. doi: 10.1620/tjem.126.133. [DOI] [PubMed] [Google Scholar]
  • 32.Monaco F, Fumero S, Mondino A, Mutani R. Plasma and cerebrospinal fluid tryptophan in multiple sclerosis and degenerative diseases. J Neurol Neurosurg Psychiatry. 1979;42:640–641. doi: 10.1136/jnnp.42.7.640. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Westall FC, Hawkins A, Ellison GW, Myers LW. Abnormal glutamic acid metabolism in multiple sclerosis. J Neurol Sci. 1980;47:353–364. doi: 10.1016/0022-510x(80)90088-x. [DOI] [PubMed] [Google Scholar]
  • 33.a. Scriver CR, Clow CL, Lamm P. Plasma amino acids: screening, quantitation and interpretation. Am J Clin Nutr. 1971;24:876–890. doi: 10.1093/ajcn/24.7.876. [DOI] [PubMed] [Google Scholar]
  • 34.Isager H. Serum folate in patients with multiple sclerosis. Acta Neurol Scand. 1970;46:238–242. doi: 10.1111/j.1600-0404.1970.tb05619.x. [DOI] [PubMed] [Google Scholar]
  • 35.Grant HC, Hoffbrand AV, Wells DG. Folate deficiency and neurological disease. Lancet. 1965;2:763–767. doi: 10.1016/s0140-6736(65)90813-5. [DOI] [PubMed] [Google Scholar]
  • 36.Wikstrom J, Westermarck T, Palo J. Selenium, vitamin E and copper in multiple sclerosis. Acta Neurol Scand. 1976;54:287–290. doi: 10.1111/j.1600-0404.1976.tb04806.x. [DOI] [PubMed] [Google Scholar]
  • 37.Swank RL. Blood plasma in multiple sclerosis. Arch Neurol Psychiat. 1953;69:281–292. doi: 10.1001/archneurpsyc.1953.02320270002001. [DOI] [PubMed] [Google Scholar]
  • 38.Rieder HP, Peyer C. Sex differences in the serum lipoprotein relations of normal persons and multiple sclerosis patients. Clin Chim Acta. 1970;30:305–310. doi: 10.1016/0009-8981(70)90117-8. [DOI] [PubMed] [Google Scholar]
  • 39.Wu J-Y, Welch KMA, Duncan CC. Abnormal protein patterns in multiple sclerosis. Neurochem Res. 1979;4:811–819. doi: 10.1007/BF00964477. [DOI] [PubMed] [Google Scholar]
  • 40.Minchin HG, Freeman CT, Pryse-Phillips WEM. Serum protein values among patients with multiple sclerosis. Clin Chim Acta. 1970;30:65–68. doi: 10.1016/0009-8981(70)90193-2. [DOI] [PubMed] [Google Scholar]
  • 41.Dowling PC, Cook SD. Disease markers in acute multiple sclerosis. Arch Neurol. 1976;33:668–670. doi: 10.1001/archneur.1976.00500100002003. [DOI] [PubMed] [Google Scholar]
  • 42.Cook SD, Menonna J, Dowling PC. Serologic abnormalities in multiple sclerosis. Neurology. 1978;28:129–131. doi: 10.1212/wnl.28.9_part_2.129. [DOI] [PubMed] [Google Scholar]
  • 43.Mar P, Gradl T, Dorner C, Contag I. A longitudinal study of immunological parameters in multiple sclerosis: cell-mediated immunity and complement profiles. Clin Exp Immunol. 1979;36:442–448. [PMC free article] [PubMed] [Google Scholar]
  • 44.Delasnerie-Laupretre N, Prevot D, Martin-Mondiere C, Eizenbaum J-F, Degos J-D, Sobel AT. Serum and cerebrospinal fluid C2 in multiple sclerosis. J Clin Lab Immunol. 1981;6:23–25. [PubMed] [Google Scholar]
  • 45.Becus T, Popoviciu L, Palade C. Study of serum and cerebrospinal fluid ceruloplasmin in multiple sclerosis and other neurologic diseases. Rev Roum Neurol. 1971;8:3–12. [PubMed] [Google Scholar]
  • 46.Rastogi SC, Clausen J. Abnormalities in native and dissociated α2-macroglobulin isolated from multiple sclerosis serum. Clin Chim Acta. 1980;107:141–144. doi: 10.1016/0009-8981(80)90424-6. [DOI] [PubMed] [Google Scholar]
  • 47.Rastogi SC, Clausen J, Fog T. Abnormal serum α2-macroglobulin in multiple sclerosis. Eur Neurol. 1981;20:33–39. doi: 10.1159/000115202. [DOI] [PubMed] [Google Scholar]
  • 48.Riekkinen PJ, Clausen J, Frey HJ, Fog T, Rinne UK. Acid proteinase activity of white matter and plaques in multiple sclerosis. Acta Neurol Scand. 1970;46:349–353. doi: 10.1111/j.1600-0404.1970.tb05799.x. [DOI] [PubMed] [Google Scholar]
  • 49.Bridges MA, Applegarth DA, Johannson J. Assessment of protease-binding by α2-macroglobulin in multiple sclerosis. Clin Chim Acta. 1982;121:167–172. doi: 10.1016/0009-8981(82)90055-9. [DOI] [PubMed] [Google Scholar]
  • 50.Krzalic L. Prealbumin content of cerebrospinal fluid and sera in persons with multiple sclerosis. Clin Chim Acta. 1982;124:339–341. doi: 10.1016/0009-8981(82)90427-2. [DOI] [PubMed] [Google Scholar]
  • 51.Degre M, Dahl H, Vandvik B. Interferon in the serum and cerebrospinal fluid in patients with multiple sclerosis and other neurological disorders. Acta Neurol Scand. 1976;53:152–160. doi: 10.1111/j.1600-0404.1976.tb04333.x. [DOI] [PubMed] [Google Scholar]
  • 52.Salonen R, Honen J, Reunanen M, Nikoskelainen J, Salmi A. PPD-, PMW-, and PHA-induced interferon in stable multiple sclerosis: association with HLA-Dw2 antigen and clinical variables. Ann Neurol. 1981;11:279–284. doi: 10.1002/ana.410110308. [DOI] [PubMed] [Google Scholar]
  • 53.Interferon nomenclature. Nature (London) 1980;286:110. doi: 10.1038/286110a0. Anonymous. [DOI] [PubMed] [Google Scholar]
  • 54.Rieder HP, Zurfluh H, Jegge S. The activity of γ-glutamyltransferase in the serum of multiple sclerosis and other neurological diseases. Clin Chim Acta. 1977;79:211–217. doi: 10.1016/0009-8981(77)90479-x. [DOI] [PubMed] [Google Scholar]
  • 55.Penn R, Worthington DJ. Is serum γ-glutamyltransferase a misleading test? Br Med J. 1983;286:531–535. doi: 10.1136/bmj.286.6364.531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Schiele F, Guilmin A-M, Detienne H, Siest G. Gamma-glutamyltransferase activity in plasma: statistical distributions, individual variations, and reference intervals. Clin Chem. 1977;23:1023–1028. [PubMed] [Google Scholar]
  • 57.Papiha SS, Roberts DF. Serum alkaline phosphatase in patients with multiple sclerosis. Clin Genet. 1975;7:77–82. doi: 10.1111/j.1399-0004.1975.tb00364.x. [DOI] [PubMed] [Google Scholar]
  • 58.MacDonald JL, Roberts DF, Shaw DA, Saunders M. Blood groups and other polymorphisms in multiple sclerosis. J Med Genet. 1976;13:30–33. [Google Scholar]
  • 59.Warner HB, Merz GS, Carp RI. Blood group frequencies in multiple sclerosis populations in the United States. Neurology. 1980;30:671–673. doi: 10.1212/wnl.30.6.671. [DOI] [PubMed] [Google Scholar]
  • 60.Mehlert A, Metcalfe RA, Diplock AT, Hughes RAC. Glutathione peroxidase deficiency in multiple sclerosis. Acta Neurol Scand. 1982;65:376–378. doi: 10.1111/j.1600-0404.1982.tb03095.x. [DOI] [PubMed] [Google Scholar]
  • 61.Jensen GE, Gissel-Nielsen G, Clausen J. Leucocyte glutathione peroxidase activity and selenium level in multiple sclerosis. J Neurol Sci. 1980;48:61–67. doi: 10.1016/0022-510x(80)90150-1. [DOI] [PubMed] [Google Scholar]
  • 62.Szeinberg A, Golan R, Ben Ezzer J, Sarova-Pinhas I, Sadeh M, Braham J. Decreased erythrocyte glutathione peroxidase activity in multiple sclerosis. Acta Neurol Scand. 1979;60:265–271. doi: 10.1111/j.1600-0404.1979.tb02980.x. [DOI] [PubMed] [Google Scholar]
  • 63.Al-Agidi SK, Roberts DF. Serum immunoglobulin levels in multiple sclerosis in Orkney. Acta Neurol Scand. 1979;60:320–327. doi: 10.1111/j.1600-0404.1979.tb02987.x. [DOI] [PubMed] [Google Scholar]
  • 64.Pandey JP, Goust J-M, Salier J-P, Fudenberg HH. Immunoglobulin G heavy chain (Gm) allotypes in multiple sclerosis. J Clin Invest. 1981;67:1797–1800. doi: 10.1172/JCI110220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.LeGac P, Wullfaert F, Arquie E, Rabinovici J, Morange D, deFougeres CT. Resultats de l'antibiotherapie a large spectre sur 30 cas chroniques de sclerose en plaques rickettsienne et neo-rickettsienne. Bull Soc Pathol Exot Filiales. 1964;57:263–276. [PubMed] [Google Scholar]
  • 66.Field EJ, Chambers M. Rickettsial antibodies in multiple sclerosis. Br Med J. 1970;1:30–32. doi: 10.1136/bmj.1.5687.30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Grist NR. Rickettsial antibodies in multiple sclerosis. Br Med J. 1970;1:363–364. doi: 10.1136/bmj.1.5692.363-b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Szekeres J, Palffy GY, Paradi J. Rickettsia specific antibodies in multiple sclerosis. Lancet. 1980;2:1089–1090. doi: 10.1016/s0140-6736(80)92319-3. [DOI] [PubMed] [Google Scholar]
  • 69.Adams JM, Imagawa DT. Vol. 111. 1962. Measles antibodies in multiple sclerosis; pp. 562–566. (Proc Soc Exp Biol Med). [DOI] [PubMed] [Google Scholar]
  • 70.Cremer NE, Johnson KP, Fein G, Likosky WH. Comprehensive viral immunology of multiple sclerosis. II. Analysis of serum and CSF antibodies by standard serologic methods. Arch Neurol. 1980;37:610–615. doi: 10.1001/archneur.1980.00500590034003. [DOI] [PubMed] [Google Scholar]
  • 71.Woyciechowska JL, Dambrosia J, Tzan N, Madden DL. Multiple sclerosis, antiviral antibodies. Lancet. 1982;2:1461–1462. doi: 10.1016/s0140-6736(82)91360-5. [DOI] [PubMed] [Google Scholar]
  • 72.Fewster ME, Ames FR, Botha MC. Measles antibodies and histocompatibility types in multiple sclerosis. J Neurol Sci. 1979;43:19–26. doi: 10.1016/0022-510x(79)90070-4. [DOI] [PubMed] [Google Scholar]
  • 73.Ilonen J, Reunanen M, Salmi A, Tiilikainen A. Lymphocyte blast transformation responses and viral antibodies in relation to HLA antigens in multiple sclerosis. J Neurol Sci. 1981;49:117–133. doi: 10.1016/0022-510x(81)90194-5. [DOI] [PubMed] [Google Scholar]
  • 74.Visscher BR, Sullivan CB, Detels R. Measles antibody titers in multiple sclerosis patients and HLA-matched and unmatched siblings. Neurology. 1981;31:1142–1145. doi: 10.1212/wnl.31.9.1142. [DOI] [PubMed] [Google Scholar]
  • 75.Cook SD, Dowling PC, Russell WC. Neutralizing antibodies to canine distemper and measles virus in multiple sclerosis. J Neurol Sci. 1979;41:61–70. doi: 10.1016/0022-510x(79)90140-0. [DOI] [PubMed] [Google Scholar]
  • 76.Madden DL, Wallen WC, Houff SA. Measles and canine distemper antibody. Presence in sera from patients with multiple sclerosis and matched control subjects. Arch Neurol. 1981;38:13–15. doi: 10.1001/archneur.1981.00510010039005. [DOI] [PubMed] [Google Scholar]
  • 77.Stephenson JR, ter Meulen V, Kiessling W. Search for canine-distemper-virus antibodies in multiple sclerosis. A detailed virological evaluation. Lancet. 1980;2:772–775. doi: 10.1016/s0140-6736(80)90387-6. [DOI] [PubMed] [Google Scholar]
  • 78.Wechsler SL, Meissner HC. Elevated antibody levels against measles virus P protein in sera of patients with multiple sclerosis. Infect Immun. 1983;40:1226–1229. doi: 10.1128/iai.40.3.1226-1229.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Poskanzer DC, Sever JL, Sheridan JL, Prenney LB. Multiple sclerosis in the Orkney and Shetland Islands. IV. Viral antibody titres and viral infections. J Epidem Commun Health. 1980;34:258–264. doi: 10.1136/jech.34.4.258. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Bray PF, Bloomer LC, Salmon VC, Bagley MH, Larsen PD. Epstein-Barr virus infection and antibody synthesis in patients with multiple sclerosis. Arch Neurol. 1983;40:406–408. doi: 10.1001/archneur.1983.04050070036006. [DOI] [PubMed] [Google Scholar]
  • 81.Arnadottir T. Measles and canine distemper virus antibodies in patients with multiple sclerosis determined by radioimmunoassay. Acta Neurol Scand. 1980;62:81–89. doi: 10.1111/j.1600-0404.1980.tb03007.x. [DOI] [PubMed] [Google Scholar]
  • 82.Leinikki PO, Holmes KV, Shekarchi I, Iivanainen M, Madden D, Sever JL. Coronavirus antibodies in patients with multiple sclerosis. Adv Exp Med Biol. 1981;142:323–326. doi: 10.1007/978-1-4757-0456-3_26. [DOI] [PubMed] [Google Scholar]
  • 83.Hovanec DL, Flanagan TD. Detection of antibodies to human corona-viruses 229E and OC43 in the sera of multiple sclerosis patients and normal subjects. Infect Immun. 1983;41:426–429. doi: 10.1128/iai.41.1.426-429.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Ryberg B. Complement-fixing antibrain antibodies in multiple sclerosis. Acta Neurol Scand. 1976;54:1–12. doi: 10.1111/j.1600-0404.1976.tb07616.x. [DOI] [PubMed] [Google Scholar]
  • 85.Ryberg B. Intrathecal and extrathecal production of antibrain antibodies in multiple sclerosis. J Neurol Sci. 1980;48:1–8. doi: 10.1016/0022-510x(80)90145-8. [DOI] [PubMed] [Google Scholar]
  • 86.Ryberg B, Kronvall G. Immunoglobulin characterization by bacterial absorption of antibrain antibodies in multiple sclerosis. Eur Neurol. 1981;20:374–379. doi: 10.1159/000115264. [DOI] [PubMed] [Google Scholar]
  • 87.Ryberg B. Multiple sclerosis: search for a serologic inhibitor. Acta Neurol Scand. 1980;62:193–196. doi: 10.1111/j.1600-0404.1980.tb03023.x. [DOI] [PubMed] [Google Scholar]
  • 88.Ryberg B. Antibrain antibodies in multiple sclerosis. Relation to clinical variables. J Neurol Sci. 1982;54:239–261. doi: 10.1016/0022-510x(82)90185-x. [DOI] [PubMed] [Google Scholar]
  • 89.Ryberg B. A longitudinal study of antibrain antibodies in multiple sclerosis. J Neurol Sci. 1982;54:263–270. doi: 10.1016/0022-510x(82)90186-1. [DOI] [PubMed] [Google Scholar]
  • 90.Daar AS, Fabre JW. Organ-specific IgM autoantibodies to liver, heart and brain in man: generalized occurrence and possible functional significance in normal individuals, and studies in patients with multiple sclerosis. Clin Exp Immunol. 1981;45:37–47. [PMC free article] [PubMed] [Google Scholar]
  • 91.Clausen J. Serum antibodies against cytosol antigens in multiple sclerosis. J Neurol Sci. 1983;60:205–216. doi: 10.1016/0022-510x(83)90063-1. [DOI] [PubMed] [Google Scholar]
  • 92.Arnon R, Crisp E, Kelley R, Ellison GW, Myers LW, Tourtellotte WW. Anti-ganglioside antibodies in multiple sclerosis. J Neurol Sci. 1980;46:179–186. doi: 10.1016/0022-510x(80)90076-3. [DOI] [PubMed] [Google Scholar]
  • 93.Mullin BR, Montanaro AJ, Reid JD, Nishimura RN. Interaction of multiple sclerosis serum with liposomes containing ganglioside GM1. Ann Neurol. 1980;7:587–590. doi: 10.1002/ana.410070615. [DOI] [PubMed] [Google Scholar]
  • 94.Frick E, Stickl H. Specificity of antibody-dependent lymphocyte cytotoxicity against cerebral tissue constituents in multiple sclerosis. Studies with basic protein of myelin, encephalitogenic peptide, cerebrosides and gangliosides. Acta Neurol Scand. 1982;65:30–37. doi: 10.1111/j.1600-0404.1982.tb03058.x. [DOI] [PubMed] [Google Scholar]
  • 95.Ruutiainen J, Arnadottir T, Molnar G, Salmi A, Frey H. Myelin basic protein antibodies in the serum and CSF of multiple sclerosis and subacute sclerosing panencephalitis patients. Acta Neurol Scand. 1981;64:196–206. doi: 10.1111/j.1600-0404.1981.tb04399.x. [DOI] [PubMed] [Google Scholar]
  • 96.Bernard CCA, Townsend E, Randell VB, Williamson HG. Do antibodies to myelin basic protein isolated from multiple sclerosis cross-react with measles and other common virus antigens? Clin Exp Immunol. 1983;52:98–106. [PMC free article] [PubMed] [Google Scholar]
  • 97.Paterson PY, Day ED, Whitacre CC, Berenberg RA, Harter DH. Endogenous myelin basic protein-serum factors (MBP-SFs) and anti-MBP antibodies in humans. J Neurol Sci. 1981;52:37–51. doi: 10.1016/0022-510x(81)90132-5. [DOI] [PubMed] [Google Scholar]
  • 98.Kennedy PGE, Lisak RP. A search for antibodies against glial cells in the serum and cerebrospinal fluid of patients with multiple sclerosis and Guillain-Barré syndrome. J Neurol Sci. 1979;44:125–133. doi: 10.1016/0022-510x(79)90230-2. [DOI] [PubMed] [Google Scholar]
  • 99.Traugott U, Snyder S, Raine CS. Oligodendrocyte staining by multiple sclerosis serum is nonspecific. Ann Neurol. 1979;6:13–20. doi: 10.1002/ana.410060104. [DOI] [PubMed] [Google Scholar]
  • 100.Steck AJ, Regli F. Oligodendrocyte-binding antibodies in multiple sclerosis: 125I-protein A studies. Neurology. 1980;30:540–542. doi: 10.1212/wnl.30.5.540. [DOI] [PubMed] [Google Scholar]
  • 101.Ma BI, Joseph BS, Walsh MJ, Potvin AR, Tourtellotte WW. Multiple sclerosis serum and cerebrospinal fluid immunoglobulin binding to Fc receptors of oligodendrocytes. Ann Neurol. 1981;9:371–377. doi: 10.1002/ana.410090410. [DOI] [PubMed] [Google Scholar]
  • 102.Singh VK, Mashal RD. Immunofluorescent staining of rat brain glial cells with multiple sclerosis serum. Can J Neurol Sci. 1981;8:143–145. doi: 10.1017/s0317167100043055. [DOI] [PubMed] [Google Scholar]
  • 103.Mar P. Antibody-dependent cellular cytotoxicity in multiple sclerosis. J Neurol Sci. 1980;47:285–303. doi: 10.1016/0022-510x(80)90012-x. [DOI] [PubMed] [Google Scholar]
  • 104.Schocket AL, Weiner HL, Walker J, McIntosh K, Kohler PF. Lymphocytotoxic antibodies in multiple sclerosis. Clin Immunol Immunopath. 1977;7:15–23. doi: 10.1016/0090-1229(77)90025-3. [DOI] [PubMed] [Google Scholar]
  • 105.McMillan SA, Haire M, Middleton D. Antibodies to lymphocytes and smooth muscle in the sera of patients with multiple sclerosis. Clin Immunol Immunopath. 1980;16:374–385. doi: 10.1016/0090-1229(80)90143-9. [DOI] [PubMed] [Google Scholar]
  • 106.Rumbach L, Tongio MM, Warter JM, Marescaux C, Mayer S, Rohmer F. Lymphocytotoxic and monocytotoxic antibodies in the serum and cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol. 1982;3:263–273. doi: 10.1016/0165-5728(82)90030-3. [DOI] [PubMed] [Google Scholar]
  • 107.Scott CF, Spitler L. Lymphocytotoxic antibody in multiple sclerosis: activity against T cell subsets and correlation with disease activity. Clin Exp Immunol. 1983;53:133–139. [PMC free article] [PubMed] [Google Scholar]
  • 108.Tsukamoto T, Ebina T, Takase S, Itahara K, Ishida N. Increased frequency of lymphocytotoxic antibodies in patients with multiple sclerosis correlated with disease activity. Tohoku J Exp Med. 1982;136:121–128. doi: 10.1620/tjem.136.121. [DOI] [PubMed] [Google Scholar]
  • 109.Armentrout SA, Sweet PM, Galant SP. The effect of a factor from multiple sclerosis serum on isolated T and B lymphocytes. J Clin Lab Immunol. 1981;5:133–136. [PubMed] [Google Scholar]
  • 110.Mogensen JT, Zeeberg IE, Clausen J. Impaired inhibition of mitogenic response of peripheral blood mononuclear cells by serum from patients with multiple sclerosis. J Clin Lab Immunol. 1981;5:11–15. [PubMed] [Google Scholar]
  • 111.Weiner HL, Hauser SL. Neuroimmunology I: Immunoregulation in neurological disease. Ann Neurol. 1982;11:437–449. doi: 10.1002/ana.410110502. [DOI] [PubMed] [Google Scholar]
  • 112.Lenhard V, Diehm H, Romer W, Rauterberg EW, Kownatzki E, Roelcke D. A “spontaneous” cold-reactive IgM antibody with anti-HLA-B8 specificity in a patient with multiple sclerosis. Immunobiology. 1982;160:382–391. doi: 10.1016/S0171-2985(82)80002-8. [DOI] [PubMed] [Google Scholar]
  • 113.Kiessling WR, Pflughaupt KW. Antithyroid antibodies in multiple sclerosis. Lancet. 1980;1:41. doi: 10.1016/s0140-6736(80)90575-9. [DOI] [PubMed] [Google Scholar]
  • 114.Aasjord P, Nyland H. Antibodies to staphylococcal lipoteichoic acid in serum and in cerebrospinal fluid from patients with multiple sclerosis. Acta Path Microbiol Scand. 1981;89:333–338. doi: 10.1111/j.1699-0463.1981.tb02709.x. [DOI] [PubMed] [Google Scholar]
  • 115.Hyypia T, Viander M, Reunanen M, Salmi A. Antibodies to nuclear and smooth muscle antigens in multiple sclerosis and control patients. Acta Neurol Scand. 1982;65:629–635. doi: 10.1111/j.1600-0404.1982.tb03116.x. [DOI] [PubMed] [Google Scholar]
  • 116.Dore-Duffy P, Donaldson JO, Rothman BL, Zurier RB. Antinuclear antibodies in multiple sclerosis. Arch Neurol. 1982;39:504–507. doi: 10.1001/archneur.1982.00510200046008. [DOI] [PubMed] [Google Scholar]
  • 117.Singh VK. Detection of antinuclear antibody in the serum of patients with multiple sclerosis. Immunol Lett. 1982;4:317–319. doi: 10.1016/0165-2478(82)90059-1. [DOI] [PubMed] [Google Scholar]
  • 118.Ziola B, Reunanen M, Salmi A. IgM-class rheumatoid factor in serum and cerebrospinal fluid of multiple sclerosis and matched neurological control patients. J Neurol Sci. 1981;51:101–109. doi: 10.1016/0022-510x(81)90063-0. [DOI] [PubMed] [Google Scholar]
  • 119.Angers JW, Korik L, Franklin LS. The leukocyte adherence-inhibition assay as a diagnostic test for multiple sclerosis: study of a substance found in MS blood. J Lab Clin Med. 1979;93:528–534. [PubMed] [Google Scholar]
  • 120.Lehmitz R, Meyer U, Meyer-Rienecker HJ. MS-related material in blood of multiple sclerosis patients: results with the leucocyte adherence inhibition assay. J Neurol. 1983;229:263–266. doi: 10.1007/BF00313555. [DOI] [PubMed] [Google Scholar]
  • 121.Olsson JE, Nilsson K. Gamma globulins of CSF and serum in multiple sclerosis: isoelectric focusing on polyacrylamide gel and agar gel electrophoresis. Neurology. 1979;29:1383–1391. doi: 10.1212/wnl.29.10.1383. [DOI] [PubMed] [Google Scholar]
  • 122.Laurenzi MA, Link H. Comparison between agarose gel electrophoresis and isoelectric focusing of CSF for demonstration of oligoclonal immunoglobulin bands in neurological disorders. Acta Neurol Scand. 1978;58:148–156. doi: 10.1111/j.1600-0404.1978.tb02874.x. [DOI] [PubMed] [Google Scholar]
  • 123.Link H, Laurenzi MA. Immunoglobulin class and light chain type of oligoclonal bands in CSF in multiple sclerosis determined by agarose gel electrophoresis and immunofixation. Ann Neurol. 1979;6:107–110. doi: 10.1002/ana.410060205. [DOI] [PubMed] [Google Scholar]
  • 124.Vartdal F, Vandvik B, Norrby E. Viral and bacterial antibody responses in multiple sclerosis. Ann Neurol. 1980;8:248–255. doi: 10.1002/ana.410080305. [DOI] [PubMed] [Google Scholar]
  • 125.Mattson DH, Roos RP, Arnason BGW. Comparison of agar gel electrophoresis and isoelectric focusing in multiple sclerosis and subacute sclerosing panencephalitis. Ann Neurol. 1981;9:34–41. doi: 10.1002/ana.410090107. [DOI] [PubMed] [Google Scholar]
  • 126.Mehta PD, Patrick BA, Wisniewski HM. Isoelectric focusing and immunofixation of cerebrospinal fluid and serum in multiple sclerosis. J Clin Lab Immunol. 1981;6:17–22. [PubMed] [Google Scholar]
  • 127.Mehta PD, Mehta SP, Patrick BA. Identification of light chain type bands in CSF and serum oligoclonal IgG from patients with multiple sclerosis. J Neuroimmunol. 1982;2:119–129. doi: 10.1016/0165-5728(82)90003-0. [DOI] [PubMed] [Google Scholar]
  • 128.Nagelkerken LM, Aalberse RC, van Walbeek HK, Out TA. Preparation of antisera directed against the idiotype(s) of immunoglobulin G from the cerebrospinal fluid of patients with multiple sclerosis. J Immunol. 1980;125:384–389. [PubMed] [Google Scholar]
  • 129.Nagelkerken LM, van Zoonen-van Exel M, van Walbeek HK, Aalberse RC, Out TA. Analysis of cerebrospinal fluid and serum of patients with multiple sclerosis by means of anti-idiotypic antisera. J Immunol. 1982;128:1102–1106. [PubMed] [Google Scholar]
  • 130.Baird LG, Tachovsky TG, Sandberg-Wollheim M, Koprowski H, Nisonoff A. Identification of a unique idiotype in cerebrospinal fluid and serum of a patient with multiple sclerosis. J Immunol. 1980;124:2324–2328. [PubMed] [Google Scholar]
  • 131.Patzold U, Haller P, Baruth B, Liman W, Deicher H. Immune complexes in multiple sclerosis. J Neurol. 1980;222:249–260. doi: 10.1007/BF00313154. [DOI] [PubMed] [Google Scholar]
  • 132.Jans H, Heltberg A, Raun NE. Circulating immune complexes and complement in the course of multiple sclerosis. Acta Neurol Scand. 1982;66:488–496. doi: 10.1111/j.1600-0404.1982.tb06871.x. [DOI] [PubMed] [Google Scholar]
  • 133.Trouillas P, Vincent C, Revillard JV. C1q-binding circulating immune complexes in multiple sclerosis patients and their first-degree relatives: a distinctive immunological feature between sporadic and familial cases. J Clin Lab Immunol. 1980;4:77–81. [PubMed] [Google Scholar]
  • 134.Haile RW, Karavodin LM, Visscher BR, Detels R, Valdiviezo NL. Similar levels of immune complexes in cases of multiple sclerosis and their unaffected relatives. J Neuroimmunol. 1981;1:183–190. doi: 10.1016/0165-5728(81)90042-4. [DOI] [PubMed] [Google Scholar]
  • 135.Arnadottir T, Kekomaki R, Lund GA, Reunanen M, Salmi AA. Circulating immune complexes in patients with multiple sclerosis. J Neurol Sci. 1982;55:273–283. doi: 10.1016/0022-510x(82)90126-5. [DOI] [PubMed] [Google Scholar]
  • 136.Lund GA, Arnadottir T, Hukkanen V, Reunanen M, Salmi A. Characterization of immune complexes in multiple sclerosis by an antigen-specific immune complex radioimmunoassay. J Neuroimmunol. 1983;4:253–264. doi: 10.1016/0165-5728(83)90039-5. [DOI] [PubMed] [Google Scholar]
  • 137.Dasgupta MK, Warren KG, Johny KV, Dossetor JB. Circulating immune complexes in multiple sclerosis: relation with disease activity. Neurology. 1982;32:1000–1004. doi: 10.1212/wnl.32.9.1000. [DOI] [PubMed] [Google Scholar]
  • 138.Noronha ABC, Antel JP, Roos RP, Medof ME. Circulating immune complexes in neurologic disease. Neurology. 1981;31:1402–1407. doi: 10.1212/wnl.31.11.1402. [DOI] [PubMed] [Google Scholar]
  • 139.Bornstein MB, Hummelgard A. Multiple sclerosis: serum induced demyelination in tissue culture. In: Shiraki H, Yonezawa T, Kuroiwa Y, editors. The aetiology and pathogenesis of the demyelinating diseases. Japan Science Press; 1976. pp. 341–350. [Google Scholar]
  • 140.Grundke-Iqbal I, Bornstein MB. Multiple sclerosis: immunochemical studies on the demyelinating serum factor. Brain Res. 1979;160:489–503. doi: 10.1016/0006-8993(79)91075-8. [DOI] [PubMed] [Google Scholar]
  • 141.Grundke-Iqbal I, Bornstein MB. Multiple sclerosis: serum gamma globulin and demyelination in organ culture. Neurology. 1980;30:749–754. doi: 10.1212/wnl.30.7.749. [DOI] [PubMed] [Google Scholar]
  • 142.Ulrich J, Lardi H. Multiple sclerosis: demyelination and myelination inhibition of organotypic tissue cultures of the spinal cord by sera of patients with multiple sclerosis and other neurological diseases. J Neurol. 1978;218:7–16. doi: 10.1007/BF00314713. [DOI] [PubMed] [Google Scholar]
  • 143.Seil FJ, Westall FC, Romine JS, Salk J. Serum demyelinating factors in multiple sclerosis. Ann Neurol. 1983;13:664–667. doi: 10.1002/ana.410130614. [DOI] [PubMed] [Google Scholar]
  • 144.Schauf CL, Davis FA. Circulating toxic factors in multiple sclerosis: a perspective. In: Waxman SG, Ritchie JM, editors. Demyelinating disease: basic and clinical electrophysiology. Raven Press; Tokyo: 1981. pp. 267–280. [Google Scholar]
  • 145.Seil FJ. Tissue culture studies of neuroelectric blocking factors. In: Waxman SG, Ritchie JM, editors. Demyelinating disease: basic and clinical electrophysiology. Raven Press; New York: 1981. pp. 281–288. [Google Scholar]

Articles from Clinical Biochemistry are provided here courtesy of Elsevier

RESOURCES